Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Head & Neck 1Gynecologic 1

Conditions

Urinary Bladder Neoplasms 1Ovarian Neoplasms 1Head and Neck Neoplasms 1Endometrial Neoplasms 1Carcinoma, Non-Small-Cell Lung 1

Interventions

pembrolizumab 9Cetuximab 5Surveys and Questionnaires 4Cisplatin 4dostarlimab 2abemaciclib 2Standard of Care 2Docetaxel 2Carboplatin 2130-nm albumin-bound paclitaxel 2ulixertinib 1trastuzumab deruxtecan 1toripalimab 1tislelizumab 1tipifarnib 1ribociclib 1repotrectinib 1palbociclib 1olaparib 1nimotuzumab 1monalizumab 1ibrutinib 1fludarabine 1exemestane 1entrectinib 1ebselen 1durvalumab 1disitamab vedotin 1avelumab 1atezolizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Head and Neck Neoplasms × RC48 antibody × 30 days × Clear all
NCT06003231 2026-06-01

A Study of Disitamab Vedotin in Previously Treated Solid Tumors That Express HER2

Seagen Inc.

Phase 2 Active not recruiting
120 enrolled
GynecologicHead & NeckThoracic

Carcinoma, Non-Small-Cell Lung, Head and Neck Neoplasms, Ovarian Neoplasms, Endometrial Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡